Triad Isotopes Releases the Third Clinical Information Bulletin from its Institute of Clinical Learning
The Institute of Clinical Learning is publishing a Clinical Information Bulletin addressing Characteristics of Attenuation Artifacts.
Orlando Florida, March 12, 2008 – Triad Isotopes, Inc. headquartered in Orlando Florida today announced the timely release of its Institute of Clinical Learning’s Third Clinical Information Bulletin, Characteristics of Attenuation Artifacts.
The Institute of Clinical Learning was developed by Triad to provide the market with an academic based resource dedicated to advancing Nuclear Medicine through research, publishing and training. The Institute is comprised of clinicians, technologists, nuclear pharmacists and professionals that bring over 75 years of nuclear medicine, nuclear cardiology, PET / CT, nuclear pharmacy and regulatory expertise as part of the Triad Isotopes team. The Institute is a valuable resource offered by Triad Isotopes to consult on clinical and technical issues related to nuclear imaging, assist with reimbursement, develop and present continuing education for technologists and provide guidance on nuclear pharmacy or regulatory mandates.
The first Clinical Information Bulletin, published in October 2007, dealt with Diabetes, a growing concern in the medical community, and its impact on Heart Disease. The second, published in December of 2007, also dealt with attenuation artifacts, but given the international Molybdenum-99 shortage, compared the characteristics of Thallium 201 and Technetium 99-m. Triad is publishing the ICL’s third Clinical Information Bulletin to assist its customers in recognizing common attenuation artifacts. Characteristics of Attenuation Artifacts, deals with the differences in soft tissue attenuation artifacts. Please direct all questions concerning ICL Clinical Information Bulletins to Steve Heun (SHeun@triadisotopes.com).
Steve Heun, Director of Clinical Services for Triad Isotopes, and author of this Clinical Update, is heading up the Institute of Clinical Learning. Steve was previously at DuPont Pharmaceuticals and Bristol Myers Squibb Medical Imaging helping launch I.V Persantine® and Cardiolite®. Steve leads a team of three Clinical Specialists, supporting locations across the Triad delivery area. The group coordinates with the Triad staff of 73 nuclear pharmacists, some of whom serve in the 22 member dedicated PET operations team, and Triad Isotopes Quality and Safety staff, lead by Director, Brigette Nelson.
Triad Isotopes, Inc. owns and operates 22 nuclear pharmacies and 6 cyclotrons located throughout the southeast. The Triad business model combines the best independent, local nuclear pharmacies and cyclotrons with the capital and management experience of a nationwide corporation enabling Triad to continually invest in its procedures, equipment and staff. All of these resources are then deployed across the Triad network of facilities so they can focus solely on patient care in the communities they serve.
Triad Isotopes - Patient focused, Community driven.
www.triadisotopes.com |
09.04.2007 | 
